Amanote Research
Register
Sign In
BET Bromodomain Proteins Are Therapeutic Targets in CRPC
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-rw2014-098
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
May 8, 2014
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Bromodomain and Extraterminal (BET) Proteins Regulate Biliary-Driven Liver Regeneration
Journal of Hepatology
Hepatology
Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-Terminal Domain (BET) Proteins
Inhibition of Bromodomain and Extra-Terminal Proteins (BET) as a Potential Therapeutic Approach in Haematological Malignancies: Emerging Preclinical and Clinical Evidence
Therapeutic Advances in Hematology
Hematology
Applying 89Zr-Transferrin to Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins
Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition
Cancer Research
Cancer Research
Oncology
BET Protein Bromodomain Inhibitor-Based Combinations Are Highly Active Against Post-Myeloproliferative Neoplasm Secondary AML Cells
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
BET Bromodomain Inhibitors Synergize With ATR Inhibitors in Melanoma in Melanoma
Cell Death and Disease
Molecular Neuroscience
Immunology
Cell Biology
Cancer Research
Cellular
Medicine
Four Proteins Governing Overangiogenic Endothelial Cell Phenotype in Patients With Multiple Myeloma Are Plausible Therapeutic Targets
Oncogene
Cancer Research
Genetics
Molecular Biology
Small G Proteins as Novel Therapeutic Targets in Cardiovascular Medicine
Physiology
Physiology
